- Home
- AUDC vs AVIR Comparison
AUDC vs AVIR Comparison
Compare AUDC & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- AVIR
- Stock Information
- Founded
- AUDC 1992
- AVIR 2012
- Country
- AUDC Israel
- AVIR United States
- Employees
- AUDC N/A
- AVIR N/A
- Industry
- AUDC Telecommunications Equipment
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- AUDC Utilities
- AVIR Health Care
- Exchange
- AUDC Nasdaq
- AVIR Nasdaq
- Market Cap
- AUDC 270.6M
- AVIR 247.5M
- IPO Year
- AUDC 1999
- AVIR 2020
- Fundamental
- Price
- AUDC $10.74
- AVIR $3.37
- Analyst Decision
- AUDC Buy
- AVIR Hold
- Analyst Count
- AUDC 2
- AVIR 1
- Target Price
- AUDC $10.00
- AVIR $6.88
- AVG Volume (30 Days)
- AUDC 113.5K
- AVIR 528.5K
- Earning Date
- AUDC 02-04-2025
- AVIR 02-26-2025
- Dividend Yield
- AUDC 3.35%
- AVIR N/A
- EPS Growth
- AUDC 0.25
- AVIR N/A
- EPS
- AUDC 0.40
- AVIR N/A
- Revenue
- AUDC $244,181,000.00
- AVIR N/A
- Revenue This Year
- AUDC $1.06
- AVIR N/A
- Revenue Next Year
- AUDC $2.94
- AVIR N/A
- P/E Ratio
- AUDC $26.75
- AVIR N/A
- Revenue Growth
- AUDC N/A
- AVIR N/A
- 52 Week Low
- AUDC $7.70
- AVIR $2.75
- 52 Week High
- AUDC $14.45
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- AUDC 65.83
- AVIR 55.56
- Support Level
- AUDC $9.46
- AVIR $3.11
- Resistance Level
- AUDC $10.83
- AVIR $3.60
- Average True Range (ATR)
- AUDC 0.29
- AVIR 0.13
- MACD
- AUDC 0.08
- AVIR 0.00
- Stochastic Oscillator
- AUDC 94.71
- AVIR 53.17
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).